NCT00035022View on ClinicalTrials.gov

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 31, 2001

Study Completion Date

March 31, 2004

Conditions
Leukemia, LymphocyticLymphoma
Interventions
DRUG

BCX-1777

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY